{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"8.6","value":"6.0"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"30.9","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Non-Hodgkin Lymphoma (NHL): Diffuse Large B-cell Lymphoma (DLBCL)"},{"categories":[{"measurements":[{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: Follicular Lymphoma Grade 3B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"6.5","value":"4.3"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"14.8","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NIH: High-Grade B-cell Lymphoma with DLBCL Histology"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"1.0","upperLimit":"NA","value":"NA"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"11.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"NIH: Primary Mediastinal (thymic) Large B-cell Lymphoma"},{"categories":[{"measurements":[{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"28.2","upperLimit":"NA","value":"NA"},{"comment":"Median, the lower bound and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"NIH: T Cell/Histiocyte-Rich Large B-Cell Lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"8.6","value":"6.4"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"12.2","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Diffuse Large B-cell Lymphoma (DLBCL): DLBCL NOS de novo"},{"categories":[{"measurements":[{"comment":"the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"1.2","upperLimit":"NA","value":"3.4"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"2.3","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"DLBCL: DLBCL from Transformed Indolent NHL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"6.4","value":"4.6"},{"comment":"the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"6.2","upperLimit":"NA","value":"14.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"DLBCL: Germinal Center B-cell like (GCB)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"9.4","value":"7.5"},{"comment":"the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"6.6","upperLimit":"NA","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"DLBCL: Activated B-cell-like, non-GCB"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"6.5","value":"4.3"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"14.8","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"NHL: Double-hit lymphoma (DBL)/triple-hit lymphoma (THL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"9.4","value":"6.4"},{"comment":"Median and the upper bound of the 95% Confidence Interval could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"33.2","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"NHL: Non-DHL/THL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from randomization to progressive disease (PD) or death from any cause, whichever occurs first. Estimates of time to event are from Kaplan-Meier product-limit estimates. PD: LDi \\> 1.5 cm, increase by ≥ 50% from PPD nadir, an increase in LDi or SDi from nadir, 0.5 cm for lesions ≤ 2 cm, 1.0 cm for lesions \\> 2 cm. Progressive metabolic disease: Score 4 or 5 with an increase in the intensity of uptake from baseline and/or new FDG-avid.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized participants per clinical, histological and molecular subgroups that are pre-specified for PFS (subgroups are not mutually exclusive)","reportingStatus":"POSTED","timeFrame":"From randomization to progression, or death from any cause, whichever occurs first (Up to 36 months)","title":"Progression-free Survival (PFS) by Subgroups","type":"SECONDARY","unitOfMeasure":"Months"}